网络药理学揭示交泰丸通过SRC/PI3K/AKT信号通路治疗2型糖尿病的机制与活性成分
该研究采用网络药理学预测交泰丸治疗2型糖尿病(T2DM)的活性成分与靶点,并通过分子对接及体内外实验验证。结果发现交泰丸可能通过抑制SRC磷酸化、激活PI3K/AKT通路,改善T2DM小鼠糖脂代谢、胰岛素抵抗及肝脏损伤。
要点
- 交泰丸可能通过调控SRC/PI3K/AKT通路改善T2DM糖脂代谢和胰岛素抵抗。
- 网络药理学预测交泰丸含30个活性成分,涉及521个T2DM重叠靶点。
- 体内外实验显示交泰丸降低SRC磷酸化并上调PI3K/AKT磷酸化水平。
核心结论
- 交泰丸可能通过SRC/PI3K/AKT信号通路缓解T2DM的糖脂代谢紊乱和胰岛素抵抗。
研究设计与样本
- 研究采用网络药理学预测活性成分与靶点,分子对接预测结合,并用C57BL/6小鼠和HepG2细胞验证。
主要发现
- 交泰丸可降低T2DM小鼠血糖、血脂和HOMA-IR,升高HOMA-ISI,降低ALT、AST、MDA并升高SOD。
- 交泰丸降低SRC磷酸化,同时升高磷酸化PI3K、PI3K和磷酸化AKT水平,并改善肝组织形态、减少炎症和坏死。
- 体外实验显示交泰丸显著降低SRC磷酸化并增强PI3K/AKT磷酸化。
关键数值与推荐
- 网络药理学分析得到30个活性化合物、597个活性成分靶点、9631个T2DM相关基因和521个重叠候选靶点。
- GO富集显示核心通路富集于胰岛素和葡萄糖代谢。
- 分子对接显示SRC与交泰丸成分具有潜在结合。
临床怎么用
- 交泰丸可能作为T2DM的潜在治疗选择,尤其针对胰岛素抵抗和糖脂代谢紊乱。
- 临床可关注SRC/PI3K/AKT通路作为交泰丸疗效的潜在生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Jiao-tai-wan (JTW) is a traditional Chinese herbal prescription, exerts its therapeutic effects on type 2 diabetes mellitus (T2DM). However, its mechanisms and active components remain unclear. AIM OF THE STUDY: To investigate the therapeutic mechanisms of JTW in treating type 2 diabetes mellitus (T2DM), focusing on identifying active components, their targets, and validating efficacy through SRC/PI3K/AKT signaling pathway modulation in vitro and in vivo. MATERIALS AND METHODS: Active ingredients were retrieved from the Traditional Chinese Medicine System Pharmacology (TCMSP) and Comprehensive Traditional Chinese Medicine Database (TCMID). Targets for these components were identified using the ChemMapper database based on 3D structural similarity. T2DM-related genes were sourced from the DisGeNET and Gene Expression Omnibus (GEO) databases. Protein-protein interaction (PPI) analysis and functional enrichment analysis were conducted to construct a pathway network of "herbs-active ingredients-candidate targets", identifying core molecular mechanisms and key active ingredients. SwissDock was used for molecular docking to predict ligands for candidate targets. The diabetic models were established using C57BL/6 mice and human liver HepG2 cell lines. Their Effectiveness and key molecules were verified through biochemical detection and immunoblotting. RESULTS: Total 30 active compounds, 597 active ingredient targets, 9631 T2DM-related genes, and 521 overlapping candidate targets were found for JTW on T2DM. Go enrichment indicated the core pathways enriched on insulin and glucose metabolism. The auto-docking demonstrated SRC has potential binds to ingredients of JTW. In vivo, JTW can reduce blood glucose, and blood lipid levels, and HOMA-IR, and increase HOMA-ISI levels in T2DM mice with reduced ALT, AST, MDA levels and increased SOD levels. Meanwhile, decreased phosphorylation of SRC, along with increased levels of phosphorylated PI3K, PI3K, and phosphorylated AKT, were observed. HE staining of liver tissues further confirmed that JTW administration improved liver morphology, reducing inflammation and necrosis. In vitro, JTW significantly ameliorates upstream dysregulation by reducing SRC phosphorylation while enhancing phosphorylated PI3K, PI3K, and AKT phosphorylation levels. CONCLUSION: JTW may alleviate glucose, insulin resistance, and lipid metabolism disorders by the SRC/PI3K/AKT signaling pathway, that provide a novel view of potential active compounds and essential targets in treating T2DM.
引用
- Ye C, Li Y, Shi J, et al. Network pharmacology analysis revealed the mechanism and active compounds of jiao tai wan in the treatment of type 2 diabetes mellitus via SRC/PI3K/AKT signaling. J Ethnopharmacol. 2024. PMID: 39374878. doi:10.1016/j.jep.2024.118898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。